← Search & browse all drugs

iobenguane (131I)

V09IX02

Forms & Strengths

Iobenguane I-131 injection solution, 37 MBq (1 mCi)/mL
Available in single‑use vials, sterile, preservative‑free

Adult Dosing

Typical diagnostic dose 370 MBq (10 mCi) IV bolus; may repeat up to 740 MBq (20 mCi) after 2–4 weeks if needed
Adjust dose for renal impairment by 20‑30% reduction
Administer over 1–2 min, followed by normal saline flush

Pediatric Dosing

5–7 MBq/kg IV (≈0.14–0.19 mCi/kg) for diagnostic imaging
Maximum single dose 370 MBq (10 mCi) regardless of weight
Dose reduction 20% if severe renal dysfunction

Indications

Localization and staging of pheochromocytoma and extra‑adrenal paraganglioma
Detection of metastatic or recurrent neuroblastoma in children
Evaluation of sympathetic nervous system tumors for therapeutic planning

Mechanism of Action

Structural analog of norepinephrine taken up by the norepinephrine transporter (NET) in adrenergic tissue
Iodine‑131 emits gamma photons for scintigraphic imaging and beta particles for limited therapeutic effect

Contraindications

Pregnancy or lactation (radioiodine exposure to fetus/infant)
Known hypersensitivity to iobenguane or any component of the formulation
Uncontrolled hypertension or severe cardiovascular instability

Adverse Reactions

Transient hypertension or tachycardia during/after injection
Nausea, vomiting, abdominal discomfort
Mild infusion site pain or erythema
Rare myelosuppression with high cumulative doses
Potential radiation‑induced thyroid uptake – administer thyroid blockade if indicated

Drug Interactions

NET inhibitors (e.g., desipramine, reserpine, cocaine, labetalol) markedly reduce tumor uptake
Sympathomimetic agents may exacerbate hypertensive response
Thyroid blocking agents (e.g., potassium iodide) reduce non‑target thyroid radiation

Curated Content: Needs Vetting Before Put to Clinical Use